ArticleFrontiers in immunology2023
Active regression model for clinical grading of COVID-19.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the therapeutic process of COVID-19, the majority of indicators that physicians have for assisting treatment have come from clinical tests represented by proteins, metabolites, and immune levels in patients' blood. Therefore, this study constructs an individualized treatment model based on deep learning methods, aiming to realize timely intervention based on clinical test indicator data of COVID-19 patients and provide an important theoretical basis for optimizing medical resource allocation. Methods: This study collected clinical data from a total of 1,799 individuals, including 560 controls for non-respiratory infectious diseases (Negative), 681 controls for other respiratory virus infections (Other), and 558 coronavirus infections (Positive) for COVID-19. We first used the Student T-test to screen for statistically significant differences (Pvalue<0.05); we then used the Adaptive-Lasso method stepwise regression to screen the characteristic variables and filter the features with low importance; we then used analysis of covariance to calculate the correlation between variables and filter the highly correlated features; and finally, we analyzed the feature contribution and screened the best combination of features. Results: Feature engineering reduced the feature set to 13 feature combinations. The correlation coefficient between the projected results of the artificial intelligence-based individualized diagnostic model and the fitted curve of the actual values in the test group was 0.9449 which could be applied to the clinical prognosis of COVID-19. In addition, the depletion of platelets in patients with COVID-19 is an important factor affecting their severe deterioration. With the progression of COVID-19, there is a slight decrease in the total number of platelets in the patient's body, particularly as the volume of larger platelets sharply decreases. The importance of plateletCV (count*mean platelet volume) in evaluating the severity of COVID-19 patients is higher than the count of platelets and mean platelet volume. Conclusion: In general, we found that for patients with COVID-19, the increase in mean platelet volume was a predictor for SARS-Cov-2. The rapid decrease of platelet volume and the decrease of total platelet volume are dangerous signals for the aggravation of SARS-Cov-2 infection. The analysis and modeling results of this study provide a new perspective for individualized accurate diagnosis and treatment of clinical COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.